LB-100
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
LB-100 is an inhibitor of protein phosphatase 2A (PP2A) with anticancer activity, with IC50 of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells, respectively[1].
In BxPc-3, Panc-1, and SW1990 cells, LB-100 treatment reduced PP2A activity by 30-50%. LB-100 increases the intracellular doxorubicin concentration (about 2.5 times that of the control group) and makes tumor cells more sensitive to the cytotoxicity of doxorubicin[1].
In a PANC-1 mouse xenograft model, LB-100 (2 mg / kg, intraperitoneal injection) improves the efficacy of the chemotherapy drug doxorubicin. LB-100 increases tumor microvessel density and blood flow velocity on the tumor surface, and decreases tumor volume[1].
Reference:
[1]. Bai X, Zhi X, Zhang Q, et al. Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis. Cancer Lett, 2014, 355(2): 281-287.
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 268.31 |
Cas No. | 1026680-07-8 |
Formula | C13H20N2O4 |
Solubility | ≥26.8 mg/mL in H2O; insoluble in EtOH; insoluble in DMSO |
Chemical Name | 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid |
SDF | Download SDF |
Canonical SMILES | CN1CCN(C(C(C2CCC3O2)C3C(O)=O)=O)CC1 |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
Cell experiment:[1] | |
Cell lines |
Pancreatic cancer cell lines BxPc-3 and Panc-1 |
Reaction Conditions |
0.85 and 3.87 μM LB-100 |
Applications |
LB-100 showed dose-dependent inhibition of cell growth in both cell lines. The IC50 of LB-100 was 0.85 μM and 3.87 μM in BxPc-3 and Panc-1, respectively. While the IC50 of doxorubicin was 2.3 μM and 1.7 μM in BxPc-3 and Panc-1, respectively, LB-100 did not synergize with doxorubicin in both cell lines. |
Animal experiment:[1] | |
Animal models |
BALB/c nude mice bearing Panc-1 xenografts |
Dosage form |
2 mg/kg Injected intraperitoneally (i.p.) on alternate days for a total of 16 days |
Applications |
LB-100 synergistically enhanced the activity of doxorubicin in vivo. This effect was associated with increased microvessel density, blood perfusion, and doxorubicin concentrations within the xenografts. |
Note |
The technical data provided above is for reference only. |
References: 1. Bai X, Zhi X, Zhang Q, et al. Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis. Cancer Letters, 2014, 355(2): 281-287. |
质量控制和MSDS
- 批次: